Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06306131 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Ovulation in Obese Women
A Phase 2 study of Pregnancy Prevention, sponsored by InnovaGyn.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT06306131 is a Phase 2 study of Pregnancy Prevention that is actively recruiting participants, run by InnovaGyn. The registered enrollment target is 22 participants, below the 989-participant average among 4 other Pregnancy Prevention trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06306131, a Phase 2 study of Pregnancy Prevention, is actively recruiting participants, sponsored by InnovaGyn.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to compare the delay in ovulation between placebo to levonorgestrel plus meloxicam in obese women with normal menses. The main questions it aims to answer are: 1. Ovulation will be delayed by ≥7 days following the first dose of levonorgestrel plus meloxicam compared to ovulation within 3 days following the first dose of placebo. 2. There will be no difference in unscheduled vaginal bleeding or adverse events between the two treatments \[placebo versus levonorgestrel plus meloxicam\]. Participants will: * undergo two treatment cycles the 1st uses placebo and the 2nd is levonorgestrel plus meloxicam, * maintain daily diary logs for adverse events, unscheduled bleeding, and onset, cessation, and amount of menstrual bleeding, * collect daily first morning voided urine from menstrual day 9 to 24, * undergo transvaginal ultrasound for ovarian follicle development on menstrual days 9, 11,13 and 14. * allow a blood sample to be drawn on days with ultrasound scans. * Take 1st placebo and levonorgestrel plus meloxicam under observation when dominant ovarian follicle is 17 ±1.0 millimeters (mm) in diameter and 2nd dose 48 hours later. Researchers will compare the placebo cycle to levonorgestrel plus meloxicam to see if ovulation is delayed, there is unscheduled vaginal bleeding, menstrual onset is delayed or there is an abnormal amount or duration of menses, there is any difference in treatment emergent side effects and any change in vital signs
Conditions Studied
Interventions
- DRUG Levonorgestrel 0.15 milligram
- DRUG Meloxicam 15 milligram
- OTHER calcium carbonate 750 milligram
Study Locations (1)
North Carolina
- Carolina Women's Research and Wellness Center - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-12-10 |
| Est. Completion | 2025-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06306131
The ClinicalTrials.gov registry entry for NCT06306131 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 989-participant average among 4 other Pregnancy Prevention trials with a reported enrollment target (98% lower). The listed sponsor is InnovaGyn, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pregnancy Prevention appearing as the primary indexed condition, and to 3 interventions - of which Levonorgestrel 0.15 milligram is the first listed.
NCT06306131 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06306131 about?
NCT06306131 is a clinical study titled "Phase II Study of Ovulation in Obese Women". The goal of this clinical trial is to compare the delay in ovulation between placebo to levonorgestrel plus meloxicam in obese women with normal menses. The main questions it aims to answer are: 1. Ovulation will be delayed by ≥7 days following the first dose of levonorgestrel plus meloxicam compar...
What is the current status of trial NCT06306131?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2023-12-10. Estimated completion is 2025-11-30.
What conditions does trial NCT06306131 study?
This clinical trial studies the following conditions: Pregnancy Prevention.
What interventions are being tested in trial NCT06306131?
The interventions under investigation include: Levonorgestrel 0.15 milligram (DRUG), Meloxicam 15 milligram (DRUG), calcium carbonate 750 milligram (OTHER).
Who is sponsoring clinical trial NCT06306131?
This trial is sponsored by InnovaGyn, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06306131 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pregnancy Prevention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days
RECRUITING · Phase 2
-
Healthy Adolescent Transitions (HAT)
COMPLETED · Phase 2
-
The Impact of Online Educator Mircoskill Training and Parent Microskill Training on Student Sexual-Health Related Outcomes
COMPLETED · NA
-
A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.